CWG
ESPR

C WorldWide Group’s Esperion Therapeutics ESPR Stock Holding History

C WorldWide Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,874
Closed -$224K – 117
2018
Q4 		$224K Sell
4,874
-125
-3% -$6.02K ﹤0.01% 117
2018
Q3 		$222K Buy
4,999
+695
+16% +$31.9K ﹤0.01% 126
2018
Q2 		$169K Hold
4,304
– – ﹤0.01% 126
2018
Q1 		$311K Sell
4,304
-129
-3% -$9.47K ﹤0.01% 115
2017
Q4 		$292K Sell
4,433
-579
-12% -$31.2K ﹤0.01% 113
2017
Q3 		$251K Buy
5,012
+765
+18% +$36.9K ﹤0.01% 121
2017
Q2 		$197K Sell
4,247
-353
-8% -$13K ﹤0.01% 121
2017
Q1 		$162K Buy
+4,600
New +$105K ﹤0.01% 124
2016
Q4 		– Sell
-19,000
Closed -$263K – 126
2016
Q3 		$263K Hold
19,000
– – ﹤0.01% 123
2016
Q2 		$188K Hold
19,000
– – ﹤0.01% 113
2016
Q1 		$321K Hold
19,000
– – 0.01% 116
2015
Q4 		$423K Buy
19,000
+10,960
+136% +$277K 0.01% 127
2015
Q3 		$190K Buy
8,040
+140
+2% +$8.79K ﹤0.01% 130
2015
Q2 		$646K Buy
+7,900
New +$773K 0.01% 119

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

C WorldWide Group's ESPR Position: Q1 2019 in Review

C WorldWide Group sold out of Esperion Therapeutics (ESPR) in Q1 2019, closing a stake of 4,874 shares — an estimated $224K sold.

C WorldWide Group first reported a position in ESPR in Q2 2015 and held it in 14 quarters. The position peaked at $646K in Q2 2015. 163 funds tracked by Wall St. Rank hold ESPR as of Q1 2019.

  • C WorldWide Group reported no remaining Esperion Therapeutics position as of Q1 2019 after selling out during the quarter.
  • C WorldWide Group sold 4,874 Esperion Therapeutics shares in Q1 2019, an estimated $224K.
  • C WorldWide Group first reported a position in Esperion Therapeutics in Q2 2015 and held it in 14 quarters.
  • C WorldWide Group's Esperion Therapeutics position peaked at $646K in Q2 2015.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2019.

Based on C WorldWide Group's 13F filing for Q1 2019, filed 3 May 2019.